Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy

Paclitaxel (PTX) has been used for cancer treatment for decades and has become one of the most successful chemotherapeutics in the clinic and financially. However, serious problems with its use still exist, owing to its poor solubility and non-selective toxicity. With respect to these issues, recent...

Full description

Bibliographic Details
Main Authors: Yuan Ma, Sifan Yu, Shuaijian Ni, Baoxian Zhang, Angela Chun Fai Kung, Jin Gao, Aiping Lu, Ge Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.626910/full
id doaj-57a22cdf28b244f4b972cc3467529c7c
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Yuan Ma
Yuan Ma
Yuan Ma
Yuan Ma
Sifan Yu
Sifan Yu
Sifan Yu
Shuaijian Ni
Shuaijian Ni
Shuaijian Ni
Shuaijian Ni
Baoxian Zhang
Baoxian Zhang
Angela Chun Fai Kung
Angela Chun Fai Kung
Jin Gao
Jin Gao
Aiping Lu
Aiping Lu
Aiping Lu
Aiping Lu
Ge Zhang
Ge Zhang
Ge Zhang
Ge Zhang
spellingShingle Yuan Ma
Yuan Ma
Yuan Ma
Yuan Ma
Sifan Yu
Sifan Yu
Sifan Yu
Shuaijian Ni
Shuaijian Ni
Shuaijian Ni
Shuaijian Ni
Baoxian Zhang
Baoxian Zhang
Angela Chun Fai Kung
Angela Chun Fai Kung
Jin Gao
Jin Gao
Aiping Lu
Aiping Lu
Aiping Lu
Aiping Lu
Ge Zhang
Ge Zhang
Ge Zhang
Ge Zhang
Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy
Frontiers in Cell and Developmental Biology
paclitaxel
ligand
small molecule
antibody
aptamer
author_facet Yuan Ma
Yuan Ma
Yuan Ma
Yuan Ma
Sifan Yu
Sifan Yu
Sifan Yu
Shuaijian Ni
Shuaijian Ni
Shuaijian Ni
Shuaijian Ni
Baoxian Zhang
Baoxian Zhang
Angela Chun Fai Kung
Angela Chun Fai Kung
Jin Gao
Jin Gao
Aiping Lu
Aiping Lu
Aiping Lu
Aiping Lu
Ge Zhang
Ge Zhang
Ge Zhang
Ge Zhang
author_sort Yuan Ma
title Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy
title_short Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy
title_full Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy
title_fullStr Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy
title_full_unstemmed Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy
title_sort targeting strategies for enhancing paclitaxel specificity in chemotherapy
publisher Frontiers Media S.A.
series Frontiers in Cell and Developmental Biology
issn 2296-634X
publishDate 2021-03-01
description Paclitaxel (PTX) has been used for cancer treatment for decades and has become one of the most successful chemotherapeutics in the clinic and financially. However, serious problems with its use still exist, owing to its poor solubility and non-selective toxicity. With respect to these issues, recent advances have addressed the water solubility and tumor specificity related to PTX application. Many measures have been proposed to remedy these limitations by enhancing tumor recognition via ligand-receptor-mediated targeting as well as other associated strategies. In this review, we investigated various kinds of ligands that have emerged as PTX tumor-targeting tools. In particular, this article highlights small molecule-, protein-, and aptamer-functionalized conjugates and nanoparticles (NPs), providing a promising approach for PTX-based individualized treatment prospects.
topic paclitaxel
ligand
small molecule
antibody
aptamer
url https://www.frontiersin.org/articles/10.3389/fcell.2021.626910/full
work_keys_str_mv AT yuanma targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT yuanma targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT yuanma targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT yuanma targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT sifanyu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT sifanyu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT sifanyu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT shuaijianni targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT shuaijianni targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT shuaijianni targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT shuaijianni targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT baoxianzhang targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT baoxianzhang targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT angelachunfaikung targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT angelachunfaikung targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT jingao targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT jingao targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT aipinglu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT aipinglu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT aipinglu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT aipinglu targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT gezhang targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT gezhang targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT gezhang targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
AT gezhang targetingstrategiesforenhancingpaclitaxelspecificityinchemotherapy
_version_ 1724199064018354176
spelling doaj-57a22cdf28b244f4b972cc3467529c7c2021-03-29T05:37:37ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2021-03-01910.3389/fcell.2021.626910626910Targeting Strategies for Enhancing Paclitaxel Specificity in ChemotherapyYuan Ma0Yuan Ma1Yuan Ma2Yuan Ma3Sifan Yu4Sifan Yu5Sifan Yu6Shuaijian Ni7Shuaijian Ni8Shuaijian Ni9Shuaijian Ni10Baoxian Zhang11Baoxian Zhang12Angela Chun Fai Kung13Angela Chun Fai Kung14Jin Gao15Jin Gao16Aiping Lu17Aiping Lu18Aiping Lu19Aiping Lu20Ge Zhang21Ge Zhang22Ge Zhang23Ge Zhang24Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, ChinaIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, ChinaIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongIncreasepharm (Hong Kong) Limited, Hong Kong Science Park, Shatin, Hong KongIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongIncreasepharm (Hong Kong) Limited, Hong Kong Science Park, Shatin, Hong KongIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongIncreasepharm (Hengqin) Institute Co. Limited, Zhuhai, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, ChinaIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong KongInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, ChinaIncreasepharm and Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery, Hong Kong Science Park, New Territories, Hong KongPaclitaxel (PTX) has been used for cancer treatment for decades and has become one of the most successful chemotherapeutics in the clinic and financially. However, serious problems with its use still exist, owing to its poor solubility and non-selective toxicity. With respect to these issues, recent advances have addressed the water solubility and tumor specificity related to PTX application. Many measures have been proposed to remedy these limitations by enhancing tumor recognition via ligand-receptor-mediated targeting as well as other associated strategies. In this review, we investigated various kinds of ligands that have emerged as PTX tumor-targeting tools. In particular, this article highlights small molecule-, protein-, and aptamer-functionalized conjugates and nanoparticles (NPs), providing a promising approach for PTX-based individualized treatment prospects.https://www.frontiersin.org/articles/10.3389/fcell.2021.626910/fullpaclitaxelligandsmall moleculeantibodyaptamer